Back to Search Start Over

Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay

Authors :
Michael Neumaier
Verena Haselmann
Peter Findeisen
Margot Thiaucourt
Catharina Gerhards
Maximilian Kittel
Maria-Christina Muth
Source :
International Journal of Infectious Diseases, International Journal of Infectious Diseases, Vol 105, Iss, Pp 632-638 (2021)
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Background The detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mandatory for the diagnosis, retrospective assessment of disease progression, and correct evaluation of the current infection situation in the population. Many such assays have been launched by various manufacturers. Unfortunately, the new US Food and Drug Administration emergency use regulations have resulted in a situation where laboratories have to perform their own validation studies but many of these laboratories do not have the biobank needed to conduct the studies. Methods We introduce a method that allows institutions to quickly perform a verification study in a low-prevalence infection situation. As proof of concept, we used the Roche Elecsys® anti-SARS-CoV-2 electrochemiluminescence immunoassay and an SAP-based hospital information system. The Shenzhen YHLO Biotech IgM and IgG assay targeting other surface patterns was used as a confirmatory test. Results The Roche assay demonstrated a limit of detection of 0.069 cutoff index and successfully passed the performance validation according to Clinical and Laboratory Standards Institute EP15-A3. The study population of 627 inpatients has a median age of 64 years, and approximately 13% of the group were under intensive care at the respective time point. All patients included tested negative for SARS-CoV-2 infection by quantitative reverse transcription polymerase chain reaction (cobas® 6800, Roche, Mannheim, Germany). Only one false-positive result was obtained, resulting in a specificity for the Roche Elecsys anti-SARS-CoV-2 test of 99.84% and a negative predictive value of 99.98%. Conclusions The anonymized use of residual material enables quick evaluation of anti-SARS-CoV-2 immunoassays, as shown in this work with the Roche Elecsys assay. Comparison of the control population with economic data makes it possible to validate the sampling set and therefore to determine diagnostic specificity. By use of the approach chosen, it was shown that the Roche test achieved very good results in terms of diagnostic specificity, reproducibility, and limit of detection.

Subjects

Subjects :
Male
0301 basic medicine
ECLIA, Electrochemiluminescence immunoassay
CLIA, Chemiluminescent immunoassay
Prevalence
Diagnostic Specificity
Infectious and parasitic diseases
RC109-216
Validation Studies as Topic
Antibodies, Viral
0302 clinical medicine
Germany
LoB, Limit of blank
Validation
SD, Standard deviation
030212 general & internal medicine
Serological assay
Immunoassay
COVID-19, Coronavirus disease 2019
education.field_of_study
medicine.diagnostic_test
General Medicine
Middle Aged
ELISA, Enzyme-linked immunosorbent assay
Infectious Diseases
Anti-SARS-CoV-2
Population study
Female
Microbiology (medical)
medicine.medical_specialty
CE, Conformité Européenne
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
030106 microbiology
Population
NAT, Neutralizing antibody test
Sensitivity and Specificity
Article
WHO, World Health Organization
COVID-19 Serological Testing
EUA, Emergency use authorization
03 medical and health sciences
Predictive Value of Tests
EU, European Union
Intensive care
medicine
Humans
NAAT, Nucleic acid amplification test
education
COI, Cutoff index
CV, Coefficient of variation
Aged
Retrospective Studies
Roche
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2
ICD-10, International Statistical Classification of Diseases and Related Health Problems
business.industry
qRT-PCR, Quantitative reverse transcriptase polymerase chain reaction
Disease progression
LoD, Limit of detection
Verification
Reproducibility of Results
CLSI, Clinical and Laboratory Standards Institute
COVID-19
FDA, Food and Drug Administration
Emergency medicine
Laboratories
business

Details

ISSN :
12019712
Volume :
105
Database :
OpenAIRE
Journal :
International Journal of Infectious Diseases
Accession number :
edsair.doi.dedup.....f998234eed80203147468f2d67d16359
Full Text :
https://doi.org/10.1016/j.ijid.2021.02.024